Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Boehringer Ingelheim
Fuji
Johnson and Johnson
Queensland Health
Merck
Moodys
Teva
Deloitte

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,932,273

« Back to Dashboard

Which drugs does patent 7,932,273 protect, and when does it expire?

Patent 7,932,273 protects PRADAXA and is included in one NDA.

This patent has fifty-nine patent family members in thirty-four countries.
Summary for Patent: 7,932,273
Title:3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino- ]propionic acid ethylester methansulfonate and its use as a medicament
Abstract: Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-m- ethyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
Inventor(s): Schmid; Rolf (Baltringen, DE), Sieger; Peter (Mittelbiberach, DE), Sobotta; Rainer (Ingelheim am Rhein, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:12/022,655
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,932,273

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-001 Oct 19, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-003 Nov 20, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate CAPSULE;ORAL 022512-002 Oct 19, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,932,273

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 39 862Aug 29, 2003

International Family Members for US Patent 7,932,273

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045520 ➤ Try a Free Trial
Argentina 073225 ➤ Try a Free Trial
Austria 430145 ➤ Try a Free Trial
Austria 529420 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Merck
Covington
UBS
Daiichi Sankyo
Farmers Insurance
Julphar
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.